


**Supplementary Figure S1. Study schema for xaluritamig IV monotherapy dose exploration and expansion phases**



\*Dose escalation commenced at the MABEL-defined starting dose (0.001 mg in Cohort 1) and progressed according to the dosing schema .

†Step dosing was introduced following observation of CRS and PSA declines in Cohort 5 and was only tolerable upon adjustment of the premedication. The higher priming dose tested in Cohort 6 was not tolerable even when reassessed with adjusted premedication upon clearance of 1 mg target dose in Cycle 8.

‡Cohort backfilled after being declared safe.

C, cohort; CRS, cytokine release syndrome; IV, intravenous; MABEL, minimum anticipated biological effect level; MTD, maximum tolerated dose; PSA, prostate-specific antigen; Q2W, every 2 weeks.